Expression of selected genes in liver biopsy specimens in relation to early virological response in patients with chronic hepatitis C with HCV mono- and HIV/HCV co-infection

被引:4
|
作者
Jablonowska, Elzbieta [1 ]
Wojcik, Kamila [1 ]
Koslinska-Berkan, Ewa [1 ]
Szymanska, Bozena [2 ]
Omulecka, Aleksandra [3 ]
Piekarska, Anna [1 ]
机构
[1] Med Univ Lodz, Dept Infect Dis & Hepatol, PL-91347 Lodz, Poland
[2] Med Univ Lodz, Cent Lab, PL-92215 Lodz, Poland
[3] Bieganski Prov Specialist Hosp, Dept Pathol, PL-91347 Lodz, Poland
关键词
PEGYLATED INTERFERON-ALPHA; GENOME-WIDE ASSOCIATION; VIRUS-INFECTION; THERAPY; IL28B; RIBAVIRIN; SUPPRESSOR; MECHANISM; MIR-122;
D O I
10.1007/s00705-013-1930-1
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The aim of our study was to evaluate the significance of IL-28B single-nucleotide polymorphism and hepatic expression of IFI27, SOCS3 and miR-122 in order to predict early virological response (EVR) in patients infected with HCV genotype 1 or 4. The study group consisted of 65 patients: 46 with HCV mono- and 19 with HIV/HCV co-infection. Analyses of IL-28B single-nucleotide polymorphism C/T (rs12979860) in the blood and expression of SOCS3, IFI27 and miR-122 in liver biopsy samples obtained before PegIFN and ribavirin treatment were performed by the RT-PCR method. EVR was defined as a > 2log decline in HCV viremia at week 12. EVR was associated with a lower expression of IFI27 and a more frequent presence of the IL28BCC genotype. IFI27 expression was lower in patients with the CC genotype, irrespective of EVR. In multivariate logistic regression, only IL28B CC genotype and age above 40 years influenced EVR (OR =5.09 and 0.29 respectively). In contrast to IFI27, expression of miR-122 and SOCS3 in patients with different IL28B genotypes was not statistically significantly different. A correlation between miR-122 and SOCS3 was found (Rho =0.495094 p < 0.0001). Analysis of IFI27, SOCS3 and miR-122 hepatic expression does not provide substantial benefits for the prognosis of EVR. The only independent prognostic factors for EVR are age and IL28B genotype. The prognostic significance of IFI27 expression for EVR is dependent on the genetic polymorphism of IL28B.
引用
收藏
页码:1365 / 1371
页数:7
相关论文
共 45 条
  • [41] Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial
    Sulkowski, Mark
    Hezode, Christophe
    Gerstoft, Jan
    Vierling, John M.
    Mallolas, Josep
    Pol, Stanislas
    Kugelmas, Marcelo
    Murillo, Abel
    Weis, Nina
    Nahass, Ronald
    Shibolet, Oren
    Serfaty, Lawrence
    Bourliere, Marc
    Dejesus, Edwin
    Zuckerman, Eli
    Dutko, Frank
    Shaughnessy, Melissa
    Hwang, Peggy
    Howe, Anita Y. M.
    Wahl, Janice
    Robertson, Michael
    Barr, Eliav
    Haber, Barbara
    LANCET, 2015, 385 (9973) : 1087 - 1097
  • [42] Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 years follow-up of a prospective longitudinal study
    Knop, Viola
    Hoppe, Daniel
    Vermehren, Johannes
    Troetschler, Sven
    Herrmann, Eva
    Vermehren, Annika
    Friedrich-Rust, Mireen
    Sarrazin, Christoph
    Trebicka, Jonel
    Zeuzem, Stefan
    Welker, Martin-Walter
    JOURNAL OF VIRAL HEPATITIS, 2021, 28 (11) : 1604 - 1613
  • [43] Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study
    Londono, Maria-Carlota
    Riveiro-Barciela, Mar
    Ahumada, Adriana
    Munoz-Gomez, Raquel
    Roget, Merce
    Devesa-Medina, Maria J.
    Serra, Miguel Angel
    Navascues, Carmen A.
    Baliellas, Carme
    Aldamiz-Echevarria, Teresa
    Gutierrez, Maria L.
    Polo-Lorduy, Benjamin
    Carmona, Isabel
    Benlloch, Salvador
    Bonet, Lucia
    Garcia-Samaniego, Javier
    Jimenez-Perez, Miguel
    Moran-Sanchez, Senador
    Castro, Ngeles
    Delgado, Manuel
    Gea-Rodriguez, Francisco
    Martin-Granizo, Ignacio
    Montes, Maria Luisa
    Morano, Luis
    Castano, Manuel A.
    de los Santos, Ignacio
    Laguno, Montserrat
    Losa, Juan Emilio
    Montero-Alonso, Marta
    Rivero, Antonio
    de Alvaro, Cristina
    Manzanares, Amanda
    Mallolas, Josep
    Barril, Guillermina
    Gonzalez-Parra, Emilio
    Garcia-Buey, Luisa
    PLOS ONE, 2019, 14 (09):
  • [44] Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naive Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response
    Asselah, Tarik
    Moreno, Christophe
    Sarrazin, Christoph
    Gschwantler, Michael
    Fosters, Graham R.
    Craxi, Antonio
    Buggisch, Peter
    Sanai, Faisal
    Bicer, Ceyhun
    Lenz, Oliver
    Van Dooren, Gino
    Nalpas, Catherine
    Lonjon-Domanec, Isabelle
    Schlag, Michael
    Buti, Maria
    PLOS ONE, 2017, 12 (01):
  • [45] Rationale and design of TeraViC-4 study:: A phase III, randomized clinical trial to evaluate the effects of treatment duration with peginterferon alfa-2a (40-kDa) and ribavirin in naive patients with chronic hepatitis C virus infection without early virological response at week 4
    Sánchez-Tapias, JM
    Crespo, J
    Diago, M
    Pérez, R
    Romero-Gómez, M
    Muñoz-Sánchez, M
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2002, 24 (09): : 579 - 584